Tri Locum Partners LP
13F Reported Value
ⓘ$813.2M
Holdings
19
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Tri Locum Partners LP disclosed 19 positions worth $813.2M in its Form 13F-HR for Q2 2026, led by $JNJ (JOHNSON & JOHNSON) at 13.3% of the equity portfolio, followed by $VRTX and $LLY. During the quarter the fund opened 4 new positions and exited 2 — including a new stake in $ELVN and a full exit from $TMO. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Tri Locum Partners LP’s Form 13F-HR filing with the SEC under CIK 1826434.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 69.0#285
Quality
$107.9M424,945 sh - 75.4#98
Quality
$100.2M201,791 sh - 87.5#2
Quality
$91.8M76,532 sh - 44.8
Quality
$69.0M258,740 sh - 76.0
Quality
$55.3M820,479 sh - 40.8
Quality
$53.7M219,308 sh - —
Quality
$53.4M221,720 sh - —
Quality
$44.0M866,716 sh - —
Quality
$38.6M41,596 sh - 40.7
Quality
$36.7M68,273 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 JOHNSON & JOHNSON$JNJ | 69.0#285 | $107.9M | 424,945 |
 VERTEX PHARMACEUTICALS INC / MA$VRTX | 75.4#98 | $100.2M | 201,791 |
 ELI LILLY & Co$LLY | 87.5#2 | $91.8M | 76,532 |
 Ascendis Pharma A/S$ASND | 44.8 | $69.0M | 258,740 |
 DEXCOM INC$DXCM | 76.0 | $55.3M | 820,479 |
 Axsome Therapeutics, Inc.$AXSM | 40.8 | $53.7M | 219,308 |
 Jazz Pharmaceuticals plc$JAZZ | — | $53.4M | 221,720 |
 Enliven Therapeutics, Inc.$ELVN | — | $44.0M | 866,716 |
 ARGENX SE$ARGX | — | $38.6M | 41,596 |
 MADRIGAL PHARMACEUTICALS, INC.$MDGL | 40.7 | $36.7M | 68,273 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Tri Locum Partners LP's 19 positions.
Showing top 10 of 19 holdings.
Sector Allocation
Healthcare
$813.2M
Full Holdings — Tri Locum Partners LP (Q2 2026)
All 19 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $JNJ | JOHNSON & JOHNSON | $107.9M | 13.3% | +3% | 69 |
| 2 | $VRTX | VERTEX PHARMACEUTICALS INC / MA | $100.2M | 12.3% | +56% | 75.4 |
| 3 | $LLY | ELI LILLY & Co | $91.8M | 11.3% | +24% | 87.5 |
| 4 | $ASND | Ascendis Pharma A/S | $69.0M | 8.5% | +1% | 44.8 |
| 5 | $DXCM | DEXCOM INC | $55.3M | 6.8% | +18% | 76 |
| 6 | $AXSM | Axsome Therapeutics, Inc. | $53.7M | 6.6% | +253% | 40.8 |
| 7 | $JAZZ | Jazz Pharmaceuticals plc | $53.4M | 6.6% | +40% | — |
| 8 | $ELVN | Enliven Therapeutics, Inc. | $44.0M | 5.4% | NEW | — |
| 9 | $ARGX | ARGENX SE | $38.6M | 4.8% | +31% | — |
| 10 | $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $36.7M | 4.5% | -34% | 40.7 |
| 11 |  $RVMD | Revolution Medicines, Inc. | $28.4M | 3.5% | NEW | — |
| 12 |  $UTHR | UNITED THERAPEUTICS Corp | $25.5M | 3.1% | -33% | 71.3 |
| 13 |  $TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $25.3M | 3.1% | -27% | — |
| 14 |  $TARS | Tarsus Pharmaceuticals, Inc. | $20.7M | 2.5% | +30% | 55 |
| 15 |  $ISRG | INTUITIVE SURGICAL INC | $19.1M | 2.4% | -69% | 79.9 |
| 16 |  $CYTK | CYTOKINETICS INC | $16.5M | 2.0% | NEW | 28.1 |
| 17 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $11.8M | 1.4% | -17% | 22.6 |
| 18 |  $BBNX | Beta Bionics, Inc. | $7.7M | 0.9% | NEW | 29.8 |
| 19 |  $DFTX | Definium Therapeutics, Inc. | $7.7M | 0.9% | -56% | — |
New Positions (4)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Tri Locum Partners LP including:
Track Tri Locum Partners LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Tri Locum Partners LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Tri Locum Partners LP
13F Pro is an AI hedge fund tracker and stock research platform. For Tri Locum Partners LP (SEC CIK: 1826434), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Tri Locum Partners LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.